EHA 2026 | Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia
Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, presents the findings from the final analysis of the APOLLO trial (NCT0268840), a Phase III randomized study that compared arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA) to the classical AIDA regimen (ATRA + idarubicin) in patients with high-risk acute promyelocytic leukemia (APL). Dr Voso highlights that the trial met its primary endpoint, demonstrating superior event-free survival and fewer hematological side effects in the experimental arm, with updated follow-up confirming superiority and a significantly lower probability of relapse. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
